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Background. Although saturated fatty acids (FAs) have been linked to cardiovascular mortality, it is not clear
whether this outcome is attributable solely to their effects on low-density lipoprotein cholesterol (LDL-C) or
whether other risk factors are also associated with FAs. The Western Alaskan Native population, with its
rapidly changing lifestyles, shift in diet from unsaturated to saturated fatty acids and dramatic increase in
cardiovascular disease (CVD), presents an opportunity to elucidate any associations between specific FAs and
known CVD risk factors.
Objective. We tested the hypothesis that the specific FAs previously identified as related to CVD mortality are
also associated with individual CVD risk factors.
Methods. In this community-based, cross-sectional study, relative proportions of FAs in plasma and red blood
cell membranes were compared with CVD risk factors in a sample of 758 men and women aged ]35 years.
Linear regression analyses were used to analyze relations between specific FAs and CVD risk factors (LDL-C,
high-density lipoprotein cholesterol, triglycerides, C-reactive protein, systolic blood pressure, diastolic blood
pressure, heart rate, body mass index, fasting glucose and fasting insulin, 2-hour glucose and 2-hour insulin).
Results. The specific saturated FAs previously identified as related to CVD mortality, the palmitic and
myristic acids, were adversely associated with most CVD risk factors, whereas unsaturated linoleic acid
(18:2n-6) and the marine n-3 FAs were not associated or were beneficially associated with CVD risk factors.
Conclusions. The results suggest that CVD risk factors are more extensively affected by individual FAs than
hitherto recognized, and that risk for CVD, MI and stroke can be reduced by reducing the intake of palmitate,
myristic acid and simple carbohydrates and improved by greater intake of linoleic acid and marine n-3 FAs.
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A
lthough high saturated fat intake has been impli-
cated in cardiovascular disease (CVD) and athe-
rosclerosis for more than a century (1,2), specific
dietary saturated fatty acids (FAs) and their related
desaturases have only recently been shown to be asso-
ciated with CVD mortality (3,4). Concurrently, evidence

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has emerged that unsaturated FAs (linoleic acid [LA] and
long-chain omega-3 FAs) are associated with lower CVD
mortality (3,57). The Uppsala Longitudinal Study of
2,000 Adult Men (ULSAM) found that serum cholesterol
ester FA profiles were related to CV and total mortality
over 30 years (3). The saturated FAs (myristic [14:0]) and
palmitic [16:0] acids) and the unsaturated FAs (palmitoleic
[16:1], g-linolenic [18:3-6] and dihomo-g-linolenic [20:3-6]
FAs) (3) also were associated with CV mortality, whereas
LA (18:2-6) concentration was negatively associated with
30-year CV and total mortality (3).
CVD is a multi-factorial disease, involving inflamma-
tion (8,9), hypertension (10), obesity (11,12), insulin resis-
tance (13,14), diabetes (15,16), elevated heart rate (1719),
low high-density lipoprotein cholesterol (HDL-C) (20),
high low-density lipoprotein cholesterol (LDL-C) (20)
and/or high triglycerides (21).
Several randomized trials of the associations of satu-
rated and unsaturated fatty acids and CVD have been
conducted (2227). Early studies substituting polyunsa-
turated fat for saturated fat showed reduction in CVD
for high-risk participants. Later studies have focused on
omega 3 fats; while these reports have not been consistent,
the consensus is that omega 3 fats may lower the risk of
sudden death in patients with CVD (5,28).
Investigators have suggested that LDL-C concentra-
tion is the main mediator between dietary saturated FAs
and CVD (2931), but other risk factors, such as insulin
resistance, inflammation and endothelial function, are
also affected by FAs (13,14,32). Therefore, the following
questions arise: (a) which FAs are associated with specific
CVD risk factors and (b) what is the most clinically
relevant measure of FA status  its relative per cent com-
position in red blood cell (RBC) membranes or its con-
centrations in plasma (33).
The Genetics of Coronary Artery Disease in Alaska
Natives (GOCADAN) study allows examination of these
relationships in a population living in isolated villages
along the northwest coast of Alaska. This population is
currently undergoing a radical dietary change from tradi-
tional Native Alaskan foods, available primarily from the
sea, to store-bought Western foods. This change involves
a shift in dietary fat consumption from unsaturated FAs
found in fish and sea mammals (34,35) to saturated FAs
from farm animals, dairy products and manufactured fats
(e.g. shortening). CVD incidence is changing concurrently.
Whereas it was rare 40 years ago (B1/1,000) (36), CVD
prevalence among Alaska Natives is now higher than that
of the U.S. White population (37), and the prevalence and
extent of carotid plaque in Western Alaskan Natives
exceeds that of the U.S. White and African American
populations (38) and is associated with blood concentra-
tions of the saturated palmitic and myristic acids (39).
Finally, stroke incidence in this population is 50% higher
than that of the general U.S. population (40).
Measures of FAs used in previous studies range from
dietary estimates, usually by food frequency questionnaire
(FFQ) or multiple 24-hour recalls (3,41,42), to analyses
of FA content in RBCs (35) or plasma (3,35) or through
analyses of plasma lipid classes (either phospholipids or
cholesterol esters) (3,43). Measurement errors and inter-
pretation of all these measures vary. FFQs, however, may
provide less reliable estimates of dietary FA intake than
methods that measure FAs in blood (3,35,43) because
they involve inaccuracies of memory, the inability of
any questionnaire to completely reflect intake and be-
cause of incomplete nutritional databases, especially for
traditional Alaska Native foods. The current study has,
thus, been limited to analyses of FAs in plasma and RBCs
(35), as these measures reflect the interplay between
dietary and metabolic processes (44). Both of these
measures have been validated as markers of intake of
long-chain omega-3 FAs, trans FAs and, to some extent,
LA (3335).
Plasma concentrations of mono and saturated FAs
do not entirely reflect diet as they can be modified by
endogenous synthesis of carbohydrates (3), although this
process is limited in those consuming high-fat Western
diets (3). The total plasma FA biomarker used in the pre-
sent study was used successfully as a biomarker previously
in this population in a pilot intervention to reduce satu-
rated fat consumption (34). This 4-year intervention
resulted in a relative decrease of palmitate (16:0; p0.02)
concomitant with improved glucose tolerance (p0.006),
fasting glucose (p0.0001), LDL cholesterol (p0.0001)




A total of 1,214 predominantly Inupiat people 17 years
of age from 9 villages in the Norton Sound Region of
Alaska were examined between 2000 and 2004 for CVD
and associated risk factors (45). In 7 of the 9 villages, an
average of 82.6% of eligible residents participated (46).
Screenings were terminated early in 2 additional villages,
when the study reached its recruitment goal. From the
sample of 1,214 participants, all participants ]35 years
of age (N819; 361 men and 458 women) underwent
assessment of total plasma and RBC FAs; those with pre-
viously diagnosed diabetes mellitus (DM) and on medi-
cation for DM (N61) were excluded, yielding a study
population of 758. The study was approved by the Research
Ethics Review Board of the Norton Sound Health
Corporation and by the institutional review boards of
MedStar Health Research Institute and Texas Biomedical
Research Institute. All participants provided informed
consent.
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Study examination
The GOCADAN exam (45) consisted of a personal in-
terview (including lifestyle assessment, medical history
and medication use), physical examination (including
ultrasound assessment of atherosclerosis in the carotid
arteries), nutritional interview using a validated FFQ (42),
anthropometric measurements (45), blood pressure (BP)
measurements (45), heart rate measurement (18,19), elec-
trocardiogram (ECG) (19,45), blood sampling, a Rose
questionnaire (45), a Modifiable Activity Questionnaire
(45), behavioural measures (45) and laboratory analyses
(45). The methods for plasma and RBC FA composition
have been described (19,35). Apolipoprotein E (ApoE)
phenotype was determined in whole plasma by a modi-
fication of the Kamboh et al. method, in which 2 hours
of isoelectric focusing are followed by immunoblotting to
visualize the ApoE bands (45). Serum C-reactive protein
(CRP) was assayed as described previously (8). Partici-
pants with CRP10 (1.7% of sample) were excluded from
the CRP analyses.
Statistical analysis
Means, standard deviations and 95% confidence intervals
were calculated to describe the population’s chara-
cteristics. Concentrations of FAs in plasma and RBC
membranes were compared with CVD risk factors in a
sample of 758 men and women aged 34 years without
diabetes, as defined by American Diabetes Association
criteria (47). Prior to conducting analyses, distributional
properties of all traits were evaluated. All values beyond
4 standard deviations were removed, and the remaining
traits were transformed by inverse normalization prior to
analysis to meet assumptions of normality.
While a correction for multiple testing was considered,
it would have been inappropriate when the number of true
positives (i.e. true biological associations that are also
statistically significant) was likely to be a large percentage
of the multiple tests. For the current analysis, a Bonferroni
correction was not applied, because (a) RBC FA concen-
trations are less associated with some risk factors than
those in plasma and (b) the Bonferroni adjustment is
conservative and tends to produce false negatives. The
conclusions expressed in this article are based on the
plasma and RBC FA data without Bonferroni adjustment,
in concurrence with other studies of individual variables
(3,18,19,21,33,35). In addition, associations were first
identified by individual testing of each FA and risk factor
adjusted only for age. This approach provided additional
confidence in the final results and conclusions.
Statistical modelling
The CVD risk factors were adjusted for age, sex, age2,
agesex, age2sex, current smoking (Y/N), cholesterol
medication and ‘‘physical activity’’ metabolic equiva-
lents (METs). The age-squared covariate was included
to account for the effect of age, which may have a non-
linear relationship with the lipids. BP was adjusted for BP
medication, and LDL-C and HDL-C were adjusted for
ApoE phenotype. CVD risk factors evaluated were heart
rate, systolic BP (SBP), diastolic BP (DBP), mean arterial
pressure, HDL-C, LDL-C, triglycerides, CRP, 2-hour glu-
cose, 2-hour insulin, fasting glucose, fasting insulin and
body mass index (BMI).
Bivariate analyses
Bivariate analyses were conducted with Sequential Oligo-
genic Linkage Analysis Routines (SOLAR; Texas Biome-
dical Research Institute, San Antonio, TX) (48). Multiple
linear regression analyses accounting for correlations
among family members were used to analyze associations
of CVD risk factors with specific FAs, after adjustment
for relevant covariates.
Phenotypic correlations were computed between FAs
and CVD risk factors (49).
Results
Population characteristics of the study sample are shown
(Table I). Those of the full GOCADAN sample have been
described (19,35,38,45). Previous data have shown median
calories consumed from fat in the 3540% range, with
about 25% of the population maintaining a subsistence
diet with saturated fat B10% of energy intake (42).
Smoking rates are high, medication usage is low and the
women have higher BMIs than the men but similar waist
circumferences. Women have higher fasting insulin, heart
rate and HDL-C than the men. The relevant dietary
components of this cohort have been described else-
where (42). The 3 top sources of saturated FAs (myristic,
palmitic and stearic acids) found in the Western Alaskan
Native diet are from store-bought foods, mostly butter,
vegetable shortening (Crisco#), evaporated milk, beef,
cheese, creamer and chicken (42).
The relative concentrations of some FAs differ sig-
nificantly in plasma versus RBCs (Table II). Proportions
of v-3 FAs, 20:4-6 and 18:0, in RBC membrane phos-
pholipids are much higher than those in plasma (50). On
the contrary, proportions of 14:0, 16:0, 16:1-7, 18:1-9 and
18:2-6 are much higher in plasma than in RBCs.
Associations with risk factors also differ (Tables III and
IV). The associations of RBC FAs differ from those of
plasma FAs because (a) they reflect diet over 12 months
instead of 12 days, (b) FAs in RBCs are bound to
phospholipids only and (c) they reflect the tissue-selective
incorporation of FAs into the RBC membranes. The total
plasma FAs reflect those FAs bound to phospholipids and
to cholesteryl esters.
The plasma FA profiles related to risk factors in the
current study (Table III) are almost identical to those
found related to CV mortality in the ULSAM study (3).
In the present study, total plasma FA concentrations of
saturated FAs (14:0 and 16:0) and those associated with
Fatty acids linked to cardiovascular risk factors
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high saturated FA consumption (16:1, 18:3-6, and 20:3-6)
were in general positively associated with CVD risk factors
(triglycerides, LDL-C, HDL-C [negatively], CRP, SBP and
DBP, heart rate, BMI, and fasting glucose and fasting
insulin, 2-hour glucose and 2-hour insulin), while the poly-
unsaturated FAs (PUFAs), LA (18:2-6), eicosapentaenoic
acid (EPA, 20:5-3) and docosahexaenoic acid (DHA,
22:6-3) were primarily either inversely or not associated
with CVD risk factors (Table III).
Discussion
The results support the hypothesis that specific FAs pre-
viously identified as related to CV mortality (3) are
associated with specific CVD risk factors. The ULSAM
investigators found no association between CVD and
marine FAs (20:5-3 and 22:6-3), perhaps because these
FAs are not well represented in the plasma cholesterol
esters they studied (3). For similar reasons, estimates of
associations between lipoprotein cholesterol and RBC
FAs reported in the current study are of questionable
significance because the FAs related to lipoprotein cho-
lesterols are likely bound to plasma lipoproteins (Table III)
but not to the RBC FAs in membranes (Table IV) (5153).
Our results explain and are in agreement with other
clinical data. The clinical repercussions of overconsump-
tion of certain saturated FAs are clear. Research has
shown that serum FA profiles with high palmitic acid,
palmitoleic acid (16:1) and dihomo-g-linolenic acid (20:3-6),
and low proportions of LA (18:2-6) predict myocardial
infarction (54,55), stroke (56), left ventricular hypertrophy
(57) and metabolic syndrome (21,58,59). It is also known
that high saturated FA consumption increases insulin
resistance (35,58), glucose intolerance (35,58), metabolic
syndrome (58,60) and low-grade inflammation (9,14).
The sources of the clinically relevant FAs in this study
population are summarized as follows:
Myristic acid (14:0) comes mostly from store-bought
foods (butter, cream, whole milk and tropical oils).
Palmitic acid (16:0) comes mainly from store-bought
items (42), but it is also manufactured in the liver (3).
Table I. Population characteristics, Genetics of Coronary Artery Disease in Alaska Natives
Women Men
N Mean SD Median N Mean SD Median
CVD risk factors
Systolic BP (mmHg) 419 120.60 (16.8) 118 336 122.35 (14.2) 122
Diastolic BP (mmHg) 420 75.20 (9.2) 74 337 78.46 (9.58) 79
Mean arterial BP (mmHg) 419 105.47 (12.9) 104 336 106.94 (107.71) 107.3
BMI (kg/m2) 419 28.65 (6.2) 27.6 334 26.69 (5.1) 25.6
Waist (cm) 414 89.25 (14.2) 87.63 330 88.77 (12.0) 86.36
HDL-C (mg/dL) 419 66.94 (18.7) 65 337 57.39 (19.0) 54
LDL-C (mg/dL) 419 122.43 (35.1) 117 337 123.11 (36.6) 119
Triglyceride (mg/dL) 419 133.55 (77.8) 114 337 125.32 (70.8) 107
HbA1c (%) 421 5.51 (0.46) 5.41 337 5.53 (0.54) 5.5
Fasting glucose (mg/dL) 421 96.79 (17.8) 92 337 96.81 (25.1) 93
Fasting insulin (mU/mL) 420 10.86 (7.9)1 8.85 335 9.62 (9.2) 7.21
2-hour glucose (mg/dL) 282 107.54 (42.4) 102 237 93.35 (38.4) 88
2-hour insulin (mU/mL) 280 44.86 (41.9) 31.65 237 28.40 (37.4) 16.4
Heart rate (beats/minute) 383 73.75 (10.4) 72 324 71.19 (13.1) 70
C-reactive protein 420 0.426 (1.7) 0.12 337 0.338 (0.7) 0.11
Covariates
METS 337 56.62 (58.1) 37.51 289 68.95 (66.1) 49.27
Age (year) 421 51.97 (12.2) 337 51.01 (11.7)
Current smoking (%) 421 53 337 60
Cholesterol medication (%) 421 9.5 337 7.4
BP medication (%) 421 22 337 19
ApoE (n) 421 337
ApoE2 (%) 1 2
ApoE3 (%) 73 66
ApoE4 (%) 32 28
Abbreviations: ApoEapolipoprotein E; BPblood pressure; BMIbody mass index; CRPC-reactive protein; HDL-Chigh-density
lipoprotein cholesterol; LDL-Clow-density lipoprotein cholesterol; METSmetabolic equivalents.
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This FA has been associated with impaired glucose
tolerance and insulin resistance (14,36,57); development
of type 2 DM (34,35); and increased BP (35,58), BMI
(61), carotid plaque and plaque score (62). The broad
effects of this FA on CVD risk factors correspond with
data from a pilot study to reduce saturated FA consump-
tion in another cohort of Western Alaska Natives, which
resulted in reductions in plasma concentrations of pal-
mitate (16:0), stearate (18:0), LDL-C, fasting glucose, DBP
and improved glucose tolerance (35).
Palmitoleic acid (16:1) is found in macadamia oil and
marine mammals (including seal oil), but it is also a pro-
duct of endogenous lipogenesis. It is biosynthesized from
palmitate by D9D, which is upregulated by saturated fat
consumption (3) and behaves like a saturated FA, increas-
ing insulin resistance (14), heart rate (19) and cholesterol
(3). In fact, 16:1-7 raises LDL-C more than palmitic acid
(16:0) (63). Palmitoleic acid (16:1-7) and its associated
D9D activity predicted mortality most strongly in the
Swedish cohort, where it was associated with abdominal
Table II. Fatty acid proportions (% of total fatty acids) as measured in plasma (bold) and red blood cells (black), Genetics of Coronary
Artery Disease in Alaska Natives
Male (age in years) Female (age in years)
Fatty acid 3544 4554 5564 6574 p 3544 4554 5564 6574 p
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CRP NS NS NS NS NS NS NS NS NS NS 0.108 (0.026) NS
SBP 0.096 (0.031) 0.097 (0.029) NS 0.110 (0.023) 0.137 (0.002) NS NS NS NS NS NS NS
DBP 0.114 (0.013) NS NS 0.115 (0.021) 0.107 (0.021) NS 0.091 (0.048) NS NS NS NS NS
ABP 0.107 (0.018) 0.101 (0.024) NS 0.118 (0.015) 0.143 (0.002) NS 0.096 (0.031) NS NS NS NS NS
HR NS NS NS NS NS NS 0 NS 0.168 (0.0002) NS 0.209 (0.0000) 0.219 (0.0000)
BMI 0.255 (1.2E07) 0.199 (0.0000) 0.172 (0.001) 0.174 (0.001) 0.197 (0.0001) 0.190 (0.0001) 0.161 (0.001) NS 0.123 (0.012) 0.175 (0.003) NS NS
Waist 0.280 (1.5E08) 0.209 (0.0000) 0.187 (0.0000) 0.204 (0.0002) 0.193 (0.0001) 0.189 (0.0001) 0.180 (0.0002) NS 0.137 (0.006) 0.166 (0.005) NS NS
% fat 0.268 (1.2E07) 0.183 (0.0004) NS 0.207 (0.0001) 0.198 (0.0001) 0.159 (0.0018) NS NS NS NS NS NS
2-hour glucose 0.175 (0.0021) 0.166 (0.004) 0.200 (0.0005) NS 0.181 (0.001) NS 0.159 (0.005) NS NS NS NS NS
2-hour insulin 0.160 (0.007) 0.138 (0.023) (0.0001) 0.146 (0.026) 0.165 (0.005) NS 0.119 (0.046) NS NS 0.150 (0.018) NS NS
Fasting
glucose
0.100 (0.035) NS NS NS NS NS NS NS NS NS NS NS
Fasting insulin 0.282 (2.88E09) 0.195 (0.0000) NS 0.137 (0.0065) 0.23 (0.0000) 0.186 (0.0001) NS NS NS NS NS NS
HbA1c 0.141 (0.003) NS NS 0.191 (0.003) NS NS NS NS NS NS NS NS
aResults are presented as phenotypic correlation estimate (p-value). Negative associations are shown in bold. All phenotypes are adjusted for age, age2, sex, agesex, age2sex,
BMI and physical activity. BMI was not used as a covariate for the BMI analysis. Additional covariates were used as follows: lipid medications for lipids, antihypertensive medication for HR
and SBP and smoking for CRP.
Mortality data are from Warensjo et al. (3).
BMIbody mass index; BPblood pressure; CRPC-reactive protein; DBPdiastolic blood pressure; HDL-Chigh-density lipoprotein cholesterol; HRheart rate; LDL-Clow-





























































































































Mortality      NS   NS NS NS NS
Triglyceride 0.31 (0.0000) 0.33 (0.0000) 0.26 (0.0000) 0.28 (0.000) 0.211 (0.0000) NS 0.231 (0.0000) NS NS 0.17 (0.003) 0.315 (0.0000) 0.20 (0.0005)
LDL-C NS NS NS 0.146 (0.008) 0.228 (0.0000) NS NS NS 0.177 (0.001) NS 0.20 (0.0002) 0.173 (0.002)
HDL-C NS NS NS NS NS NS NS 0.122 (0.026) NS NS NS NS
CRP NS 0.091 (0.045) NS NS 0.158 (0.0004) NS NS NS 0.100 (0.037) NS 0.106 (0.018) 0.113 (0.011)
SBP NS 0.146 (0.006) NS NS 0.175 (0.0000) NS 0.109 (0.042) NS NS NS NS NS
DBP NS 0.126 (0.0024) NS NS 0.195 (0.0000) 0.144 (0.010) NS NS NS NS 0.152 (0.007) 0.117 (0.039)
MAP NS 0.148 (0.006) NS NS 0.191 (0.0000) NS NS NS NS NS NS NS
HR NS 0.178 (0.0001) 0.137 (0.002) NS 0.244 (0.0000) NS NS NS NS NS 0.116 (0.010) 0.113 (0.012)
BMI 0.128 (0.009) 0.146 (0.003) NS 0.103 (0.039) 0.091 (0.066) NS NS 0.127 (0.009) NS NS NS NS
Waist 0.161 (0.001) 0.187 (0.0002) 0.124 (0.014) 0.124 (0.015) 0.100 (0.048) NS NS 0.135 (0.007) NS NS NS NS
2-hour glucose NS 0.216 (0.0001) 0.215 (0.0001) NS 0.118 (0.033) NS NS 0.157 (0.005) NS NS NS NS
2-hour insulin NS 0.115 (0.048) NS 0.149 (0.008) 0.168 (0.004) NS NS NS NS NS 0.150 (0.009) NS
Fasting glucose NS NS NS NS NS NS NS 0.103 (0.032) NS NS NS NS
Fasting insulin 0.171 (0.0003) NS NS 0.124 (0.010) NS NS NS NS 0.106 (0.028) NS NS NS
aResults are presented as phenotypic correlation estimate (p-value). Negative associations are shown in bold. All phenotypes are adjusted for age, age2, sex, agesex, age2sex, BMI
and physical activity. BMI was not used as a covariate for the BMI analysis. Additional covariates were used as follows: lipid medications for lipids, antihypertensive medication for HR and
SBP and smoking for CRP.
Mortality data are from Warensjo et al. (3).
ABPaverage blood pressure; BMIbody mass index; CRPC-reactive protein; DBPdiastolic blood pressure; HDL-Chigh-density lipoprotein cholesterol; HRheart rate;













































































































obesity and triglyceridemia (3). Because D9D catalyses
the synthesis of 16:1-7 and 18:1-9 and is upregulated by
saturated fat (3), the high intake of saturated fat results in
increased lipogenesis and plays a key role in obesity-related
diseases (6466). In the current study, LDL-C was not
associated with either RBC phospholipid-bound FAs 16:0
or 16:1, possibly because the phospholipid fractions of the
FAs in RBC membranes have little to do with cholesterol
metabolism.
Stearic acid (18:0) was not associated with CVD mor-
tality in the Swedish study (3) and was only associated
with DBP in the RBC samples in the current study. The
relative proportion of 14:0 and 16:0 FAs is higher than
18:0 in meat from corn-fed cattle kept in feedlots than
from grass-fed cattle (67), suggesting that the fat in store-
bought meat available in village stores has a high pro-
portion of the detrimental FAs 14:0 and 16:0 (42). In the
current study, as in other studies, 18:0 appears mainly
related to risk factors for obesity and type 2 DM (15).
Gamma-linolenic acid (18:3-6) is mainly a metabolite
of 18:2-6 and is the precursor to dihomo-g-linoleic acid
(DHLA; 20:3-6), which is a precursor of arachidonic
acid.
Oleic acid (18:1-9) is derived from olive oil, canola,
butter, milk, eggs, seal oil and muktuk and can be syn-
thesized de novo from stearic acid by the action of D9D.
This FA is generally considered protective or neutral as
related to CVD risk (6870), although some researchers
have reported increased CVD risk with higher intake (28).
The latter association may be related to the mutual dietary
sources of oleic acid and saturated FAs in dairy products,
meat and poultry.
Concentration of linoleic acid (18:2-6) in serum is known
to reflect dietary intake and is negatively associated
with CVD mortality (3) and with a few CVD risk factors
(Table IV). The positive association between LA and
LDL-C in plasma samples of the current study cannot be
explained. LA is known to lower LDL-C (29,30) and
decrease riskof myocardial infarction (54). Such protective
effects have been noted in clinical and prospective studies
(3), and it has been learned in the past few years that
FA profiles with low proportions of LA (18:2-6) predict
myocardial infarction (4,55), stroke (56), left ventricular
hypertrophy (57), insulin sensitivity (14), glucose intoler-
ance (61) and metabolic syndrome (58,60). The conclusion
must be that LA is protective (i.e. LA reduces some risk
factors, thereby reducing risk for CVD and mortality).
Relative concentrations (%) of alpha-linolenic acid
(ALA, 18:3-3) in serum was only marginally (p0.06)
associated with CV mortality (3) and in this study was
associated with increased triglycerides, BMI and 2-hour
insulin scores, suggesting that this FA may have some
detrimental effects.
Marine omega-3 FAs (EPA, 20:5-3; and DHA, 22:6-3)
in RBCs were negatively associated with triglycerides,
CRP, DBP, HR and 2-hour insulin, but positively asso-
ciated with triglycerides and LDL-C in plasma FAs. The
ULSAM study found no association between EPA/DHA
and CVD mortality, but that could have resulted from
looking only at FAs in serum cholesterol esters, which
lack high concentrations of these FAs (3). These FAs, in
the Alaska Native population, are derived mainly from
salmon, sardines, seal oil and whale blubber and are con-
sidered cardioprotective, as numerous studies have shown
an inverse association with sudden cardiac arrest (28).
The conclusion from studies in Greenland, that these FAs
prevent atherosclerosis, has recently been cast into doubt
as no association has been found with the presence of
plaque in Alaska Natives (39). IMT, however, was in-
versely associated with EPA and DHA (39). The bene-
ficial effects are now believed to be related to reducing
arrhythmia (5,18,19,28), which is associated with heart
rate, which in turn is negatively associated with RBC and
plasma concentrations of EPA and DHA (19).
Differences in FA biomarkers
The results from the 2 FA measures (plasma and RBCs)
in the current study and from serum cholesterol ester
measures in the ULSAM study (3) are similar in their
identification of the FAs that are either detrimental or
protective for CV health. Differences between the FA
measures, however, are reflected in the associations of
FAs with CV risk factors. The current study shows that
the 2 measurement methods complement each other.
The FA contents of RBCs have poor associations with
cholesterol compared with the well-established associa-
tions observed with dietary and total serum FA measures
(3,32). Plasma measures of saturated FAs were asso-
ciated with plasma LDL-C concentrations in this cohort,
possibly because FAs related to cholesterol are mainly
bound to lipoproteins in the plasma. On the contrary, the
FAs in serum cholesteryl esters are thought to contain
insufficient amounts of marine v-3 FA to provide reliable
associations (3).
Conclusions
High blood concentrations of saturated fats (14:0 and
16:0) are detrimental to cardiovascular health and the
biological systems related to it, while some unsaturated
FAs (18:2-6, 20:5-3, 22:6-3) are protective.
This study has many strengths. It is the largest
population-based survey of CVD and its risk factors in
Western Alaska Natives. All methods were carefully stan-
dardized and outcomes were ascertained according to
American Heart Association/National Heart, Lung, and
Blood Institute standard procedures (71). Weaknesses are
due to the observational nature of the study, which
precludes conclusions of cause and effect. In addition,
there may be several dietary and behavioural residual
confounders that have not been measured.
Sven O. E. Ebbesson et al.
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The associations between specific FAs and CVD risk
factors observed here are consistent with the known
relations between FAs and CVD (3). Although these FA
biomarkers do not precisely reflect diet, our findings
suggest that reducing plasma concentrations of detri-
mental saturated FAs may in turn improve overall CVD
risk status. Reducing palmitate and simple carbohydrate
consumption and increasing fish oil consumption could
thus lead to a decrease in CVD, MI and stroke. The
results, therefore, demand a well-controlled intervention
study to reduce plasma concentrations of FAs linked to
CVD mortality and CVD risk factors as identified in this
article.
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